

Ke-Tao Jin

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9108955/ke-cao-jin-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

52
papers

865
citations

16
h-index

28
g-index

52
ext. papers

1,101
ext. citations

4.2
avg, IF

4.39
L-index

#	Paper	IF	Citations
52	Organoid Models for Precision Cancer Immunotherapy.. <i>Frontiers in Immunology</i> , 2022 , 13, 770465	8.4	3
51	Personalized Immunotherapy in Colorectal Cancers: Where Do We Stand?. <i>Frontiers in Oncology</i> , 2021 , 11, 769305	5.3	1
50	Whole-exome sequencing of alpha-fetoprotein producing gastric carcinoma reveals genomic profile and therapeutic targets. <i>Nature Communications</i> , 2021 , 12, 3946	17.4	5
49	Development of humanized mouse with patient-derived xenografts for cancer immunotherapy studies: A comprehensive review. <i>Cancer Science</i> , 2021 , 112, 2592-2606	6.9	8
48	The emerging therapeutic role of mesenchymal stem cells in anthracycline-induced cardiotoxicity. <i>Cell and Tissue Research</i> , 2021 , 384, 1-12	4.2	1
47	Oncolytic Virotherapy in Solid Tumors: The Challenges and Achievements. <i>Cancers</i> , 2021 , 13,	6.6	4
46	Crosstalk between oncolytic viruses and autophagy in cancer therapy. <i>Biomedicine and Pharmacotherapy</i> , 2021 , 134, 110932	7.5	8
45	Tumor-Associated Macrophages Promote Oxaliplatin Resistance METTL3-Mediated mA of TRAF5 and Necroptosis in Colorectal Cancer. <i>Molecular Pharmaceutics</i> , 2021 , 18, 1026-1037	5.6	12
44	Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer. <i>Cancer Cell International</i> , 2021 , 21, 83	6.4	4
43	Role of immune regulatory cells in breast cancer: Foe or friend?. <i>International Immunopharmacology</i> , 2021 , 96, 107627	5.8	7
42	A Systematic Review of the Potential Chemoprotective Effects of Resveratrol on Doxorubicin-Induced Cardiotoxicity: Focus on the Antioxidant, Antiapoptotic, and Anti-Inflammatory Activities. <i>Oxidative Medicine and Cellular Longevity</i> , 2021 , 2021, 2951697	6.7	3
41	Preclinical tumor organoid models in personalized cancer therapy: Not everyone fits the mold. <i>Experimental Cell Research</i> , 2021 , 408, 112858	4.2	1
40	Adenosinergic Pathway: A Hope in the Immunotherapy of Glioblastoma. <i>Cancers</i> , 2021 , 13,	6.6	5
39	Recent Trends in Nanocarrier-Based Targeted Chemotherapy: Selective Delivery of Anticancer Drugs for Effective Lung, Colon, Cervical, and Breast Cancer Treatment. <i>Journal of Nanomaterials</i> , 2020 , 2020, 1-14	3.2	23
38	Nanomedicine and Early Cancer Diagnosis: Molecular Imaging using Fluorescence Nanoparticles. <i>Current Topics in Medicinal Chemistry</i> , 2020 , 20, 2737-2761	3	5
37	Long non-coding RNA DANCR promotes colorectal tumor growth by binding to lysine acetyltransferase 6A. <i>Cellular Signalling</i> , 2020 , 67, 109502	4.9	9
36	An update on colorectal cancer microenvironment, epigenetic and immunotherapy. <i>International Immunopharmacology</i> , 2020 , 89, 107041	5.8	8

35	Modulating barriers of tumor microenvironment through nanocarrier systems for improved cancer immunotherapy: a review of current status and future perspective. <i>Drug Delivery</i> , 2020 , 27, 1248-1262	7	7
34	Current progress in the clinical use of circulating tumor cells as prognostic biomarkers. <i>Cancer Cytopathology</i> , 2019 , 127, 739-749	3.9	15
33	Luteolin inhibits cell cycle progression and induces apoptosis of breast cancer cells through downregulation of human telomerase reverse transcriptase. <i>Oncology Letters</i> , 2019 , 17, 3842-3850	2.6	24
32	A potential novel therapy for FGFR1-amplified pancreatic cancer with bone metastasis, screened by next-generation sequencing and a patient-derived xenograft model. <i>Oncology Letters</i> , 2019 , 17, 2303-2307	2.6	7
31	Garcinol inhibits cancer stem cell-like phenotype via suppression of the Wnt/ β -catenin/STAT3 axis signalling pathway in human non-small cell lung carcinomas. <i>Journal of Nutritional Biochemistry</i> , 2018 , 54, 140-150	6.3	26
30	UBASH3B promotes tamoxifen resistance and could be negatively regulated by ESR1. <i>Oncotarget</i> , 2018 , 9, 8326-8333	3.3	3
29	Microbiota-gut-brain axis and the central nervous system. <i>Oncotarget</i> , 2017 , 8, 53829-53838	3.3	131
28	Individualized drug screening based on next generation sequencing and patient derived xenograft model for pancreatic cancer with bone metastasis. <i>Molecular Medicine Reports</i> , 2017 , 16, 4784-4790	2.9	9
27	Molecular Imaging of Cancer with Nanoparticle-Based Theranostic Probes. <i>Contrast Media and Molecular Imaging</i> , 2017 , 2017, 1026270	3.2	36
26	Clinicopathological significance of SMAD4 loss in pancreatic ductal adenocarcinomas: a systematic review and meta-analysis. <i>Oncotarget</i> , 2017 , 8, 16704-16711	3.3	28
25	Genetic heterogeneity in hepatocellular carcinoma and paired bone metastasis revealed by next-generation sequencing. <i>International Journal of Clinical and Experimental Pathology</i> , 2017 , 10, 10495-10504	1.4	1
24	Totally laparoscopic D2 radical distal gastrectomy using Billroth II anastomosis: A case report. <i>Oncology Letters</i> , 2016 , 11, 1855-1858	2.6	2
23	Impact of Abdominal Shape on Short-Term Surgical Outcome of Laparoscopy-Assisted Distal Gastrectomy for Gastric Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2016 , 20, 1091-7	3.3	6
22	Establishment and characterization of GCSR1, a multi-drug resistant signet ring cell gastric cancer cell line. <i>International Journal of Oncology</i> , 2015 , 46, 2479-87	4.4	7
21	FRZB up-regulation is correlated with hepatic metastasis and poor prognosis in colon carcinoma patients with hepatic metastasis. <i>International Journal of Clinical and Experimental Pathology</i> , 2015 , 8, 4083-90	1.4	5
20	Perineural invasion: a potential reason of hepatocellular carcinoma bone metastasis. <i>International Journal of Clinical and Experimental Medicine</i> , 2015 , 8, 5839-46		4
19	Anti-angiogenesis or pro-angiogenesis for cancer treatment: focus on drug distribution. <i>International Journal of Clinical and Experimental Medicine</i> , 2015 , 8, 8369-76		24
18	FRZB up-regulated in hepatocellular carcinoma bone metastasis. <i>International Journal of Clinical and Experimental Pathology</i> , 2015 , 8, 13353-9	1.4	4

17	Clinical modalities for management of gastric cancer hepatic metastasis. <i>International Journal of Clinical and Experimental Medicine</i> , 2015 , 8, 19850-8		2
16	Antitumor effect of FP3 in a breast cancer xenograft model. <i>Experimental and Therapeutic Medicine</i> , 2013 , 5, 85-88	2.1	1
15	Mechanisms regulating colorectal cancer cell metastasis into liver (Review). <i>Oncology Letters</i> , 2012 , 3, 11-15	2.6	39
14	Antitumor effects of FP3 in combination with capecitabine on PDDT xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases. <i>Cancer Biology and Therapy</i> , 2012 , 13, 737-44	4.6	3
13	Antitumor effect of FP3 in a patient-derived tumor tissue xenograft model of gastric carcinoma through an antiangiogenic mechanism. <i>Oncology Letters</i> , 2012 , 3, 1052-1058	2.6	7
12	Antitumor effect of FP3 in combination with cetuximab on patient-derived tumor tissue xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases. <i>International Journal of Molecular Medicine</i> , 2012 , 30, 126-32	4.4	5
11	Differential response to EGFR- and VEGF-targeted therapies in patient-derived tumor tissue xenograft models of colon carcinoma and related metastases. <i>International Journal of Oncology</i> , 2012 , 41, 583-8	4.4	21
10	Assessment of a novel VEGF targeted agent using patient-derived tumor tissue xenograft models of colon carcinoma with lymphatic and hepatic metastases. <i>PLoS ONE</i> , 2011 , 6, e28384	3.7	24
9	Gallbladder carcinoma incidentally encountered during laparoscopic cholecystectomy: how to deal with it. <i>Clinical and Translational Oncology</i> , 2011 , 13, 25-33	3.6	29
8	FP3: a novel VEGF blocker with antiangiogenic effects in vitro and antitumour effects in vivo. <i>Clinical and Translational Oncology</i> , 2011 , 13, 878-84	3.6	10
7	Heterogeneity in primary tumors and corresponding metastases: could it provide us with any hints to personalize cancer therapy?. <i>Personalized Medicine</i> , 2011 , 8, 175-182	2.2	9
6	Establishment of a PDDT xenograft model of gastric carcinoma and its application in personalized therapeutic regimen selection. <i>Hepato-Gastroenterology</i> , 2011 , 58, 1814-22		18
5	Advances in combination of antiangiogenic agents targeting VEGF-binding and conventional chemotherapy and radiation for cancer treatment. <i>Journal of the Chinese Medical Association</i> , 2010 , 73, 281-8	2.8	23
4	Clinical applications of VEGF-trap (aflibercept) in cancer treatment. <i>Journal of the Chinese Medical Association</i> , 2010 , 73, 449-56	2.8	40
3	Personalized cancer therapy using a patient-derived tumor tissue xenograft model: a translational field worthy of exploring further?. <i>Personalized Medicine</i> , 2010 , 7, 597-606	2.2	6
2	Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review. <i>Clinical and Translational Oncology</i> , 2010 , 12, 473-80	3.6	161
1	Aflibercept (VEGF Trap): one more double-edged sword of anti-VEGF therapy for cancer?. <i>Clinical and Translational Oncology</i> , 2010 , 12, 526-32	3.6	21